

Ref: FOI/GS/ID 6553

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

12 February 2021

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to melanoma and breast cancer.

You asked:

- 1. How many patients are currently (in the past 3 months) undergoing treatment for melanoma, and how many of these are BRAF+?*
- 2. In the past 3 months, how many melanoma patients (any stage) were treated with the following?*
 - a. Cobimetinib*
 - b. Dabrafenib*
 - c. Dabrafenib AND Trametinib*
 - d. Encorafenib AND Binimetinib*
 - e. Ipilimumab*
 - f. Ipilimumab AND Nivolumab*
 - g. Nivolumab*
 - h. Pembrolizumab*
 - i. Trametinib*
 - j. Vemurafenib*
 - k. Vemurafenib AND Cobimetinib*
 - l. Other active systemic anti-cancer therapy*
 - m. Palliative care only*
- 3. If possible, could you please provide the patients treated in the past 3 months with the following therapies for metastatic melanoma ONLY?*
 - a. Ipilimumab*
 - b. Ipilimumab AND Nivolumab*
 - c. Nivolumab*
 - d. Pembrolizumab*
 - e. Any other therapies*
- 4. In the past 3 months how many patients were treated with the following for breast cancer?*

- a. *Abemaciclib + Anastrozole/Exemestane/Letrozole*
- b. *Abemaciclib + Fulvestrant*
- c. *Alpelisib + Fulvestrant*
- d. *Atezolizumab*
- e. *Bevacizumab*
- f. *Eribulin*
- g. *Everolimus + Exemestane*
- h. *Fulvestrant as a single agent*
- i. *Gemcitabine + Paclitaxel*
- j. *Lapatinib*
- k. *Neratinib*
- l. *Olaparib*
- m. *Palbociclib + Anastrozole/Exemestane/Letrozole*
- n. *Palbociclib + Fulvestrant*
- o. *Pertuzumab + Trastuzumab + Docetaxel*
- p. *Ribociclib + Anastrozole/Exemestane/Letrozole*
- q. *Ribociclib + Fulvestrant*
- r. *Talazoparib*
- s. *Transtuzumab + Paclitaxel*
- t. *Transtuzumab as a single agent*
- u. *Trastuzumab emtansine*
- v. *Any other active systemic anti-cancer therapy*

Trust response:

1. The Trust does not do any non-Oncology treatments for Melanoma and we do not collect BRAF+ status.

The following responses relate to the period 1/11/2020-31/1/2021.

2.

- a. 0
- b. 15
- c. 2
- d. 8
- e. 3
- f. 1
- g. 11
- h. 38
- i. 1
- j. 0
- k. 0
- l. 0

m. This information is not held on our system and would involve the manual checking of patient records.

3. We cannot definitively identify metastatic melanoma from our system and it not possible to answer this question.

The following responses relate to the period 1/11/2020-31/1/2021.

4.

- a. 0
- b. 4
- c. 0
- d. 0

e. 0
f. 5
g. 2
h. 0
i. 0
j. 0
k. 0
l. 0
m. 60
n. 20
o. 12
p. 4
q. 0
r. 0
s. 1
t. 24
u. 9
v. 106